U024 High-Yield Updates in DRESS syndrome
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Our focus session is directed to dermatologists who diagnose and manage patients with DRESS. We provide a comprehensive update on diagnostic tools, utilizing recent clinical, laboratory, and algorithm-based studies. This includes our group’s novel and comprehensive systematic review that redefines and recharacterizes the frequency and likelihood with which medicines induce this condition. Additionally, we appraise and review original, recently recognized subtypes of DRESS. This includes a new subtype with unique treatment and prognostic implications (DRESS with pustulosis) that our group described. Finally, we review a novel Delphi consensus exercise that proposes DRESS subtypes and different treatments per subtype.
LEARNING OBJECTIVES
Apply new diagnostic tools for rendering DRESS diagnosis
Utilize novel drug attribution algorithm to identify culprit medicine in DRESS
Recognize unique DRESS subtypes, their key features, and how to manage them
SCHEDULE
8:30 PM
Introduction
Abraham Korman, MD, FAAD
8:35 PM
Subtypes, identifying drug (ADDRESS score), differentiation using AI
Abraham Korman, MD, FAAD
8:55 PM
Updates in management (severity rating tools to guide treatment, novel treatments)
Caroline Nelson, MD, FAAD
9:15 PM
Controversies (viral activation, etc.)
Misha Rosenbach, MD, FAAD
9:25 PM
Wrap up/questions
SPEAKERS
Abraham Korman, MD, FAAD
Caroline Nelson, MD, FAAD
Misha Rosenbach, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Abraham Korman, MD, FAAD
No financial relationships exist with ineligible companies.
Caroline Nelson, MD, FAAD
Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Misha Rosenbach, MD, FAAD
J&J Innovative Medicine – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); Novartis – Consultant(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria);